ECONOMIC-EVALUATION OF LIPID LOWERING - A FEASIBILITY TEST OF THE CONTINGENT VALUATION APPROACH

被引:23
|
作者
JOHANNESSON, M
机构
[1] Centre for Health Economics, Stockholm School of Economics, Stockholm
关键词
CONTINGENT VALUATION; COST-BENEFIT ANALYSIS; COST-EFFECTIVENESS ANALYSIS; WILLINGNESS TO PAY; STANDARD GAMBLE; ECONOMIC EVALUATION; LIPID LOWERING; PREVENTION;
D O I
10.1016/0168-8510(92)90163-6
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
A large number of cost-effectiveness analyses of treatment of high cholesterol levels have been published the last few years. Due to the inherent problems of cost-effectiveness analysis of prevention and the specific problems in the case of lipid lowering, it is important to test alternative approaches. This study reports the results of a pilot study of three benefit measures based on individual perferences. Willingness to pay (WTP), willingness to give up leisure time (WTGT) and maximum acceptable risk (MAR) for lowering cholesterol levels to normal were investigated among persons with hypercholesterolaemia in a postal survey. The respondents were on average prepared to pay about SEK 450 per month, to give up about 7 hours of leisure time per week or to take an immediate mortality risk of about 1.4% to get normal lipid levels. The WTP and WTGT questions seemed to be about equally acceptable, whereas the MAR question performed less well with respect to acceptability. It is concluded that especially WTP deserves further attention, due to its inherent advantages, since it performed at least as well as the other measures.
引用
收藏
页码:309 / 320
页数:12
相关论文
共 38 条
  • [31] Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects
    Wisloff, Torbjorn
    Mundal, Liv J.
    Retterstol, Kjetil
    Igland, Jannicke
    Kristiansen, Ivar Sonbo
    ATHEROSCLEROSIS, 2019, 287 : 140 - 146
  • [32] An Economic Evaluation of Non-HDL-Cholesterol and Apolipoprotein B as Treatment Targets for Lipid-Lowering Therapy in Primary Prevention
    Luebbe, Samuel
    Wilkins, John
    Moran, Andrew
    Sniderman, Allan
    Kohli-Lynch, Ciaran
    CIRCULATION, 2024, 150
  • [33] Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation Introduction
    Ara, R.
    Pandor, A.
    Stevens, J.
    Rees, A.
    Rafia, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 (34) : 1 - +
  • [34] Feasibility Assessment of Simultaneous Biaxial Test Methodology by Segmentation Approach for a Supersized Wind Turbine Blade Evaluation
    Ha, Kwangtae
    Kwon, Daeyong
    Yoo, Cheol
    Kim, Kyuhong
    INTERNATIONAL JOURNAL OF PRECISION ENGINEERING AND MANUFACTURING-GREEN TECHNOLOGY, 2024, 11 (05) : 1511 - 1531
  • [35] OPTIMIZED REDUCTION OF THE MAGNETIC-FIELD NEAR SWEDISH 400 KV LINES BY ADVANCED CONTROL OF SHIELD WIRE CURRENTS - TEST-RESULTS AND ECONOMIC-EVALUATION
    JONSSON, U
    LARSSON, A
    SJODIN, JO
    IEEE TRANSACTIONS ON POWER DELIVERY, 1994, 9 (02) : 961 - 969
  • [36] Projected Cost Savings With Optimal Medication Adherence in Patients With Cardiovascular Disease Requiring Lipid-Lowering Therapy: A Multinational Economic Evaluation Study
    Cho, Jeong-Yeon
    Wilson, Fernando A.
    Chaikledkaew, Usa
    Chen, Yingyao
    Phrommintikul, Arintaya
    Diaz-Aguilera, Miguel Angel
    Chen, Zhenyue
    Kim, Kyoo
    Chaiyakunapruk, Nathorn
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (22):
  • [37] USING IQWIG'S EFFICIENCY FRONTIER APPROACH FOR THE ECONOMIC EVALUATION OF HEAPTITIS C TREATMENT-A PILOT AND FEASIBILITY STUDY COMMISSIONED BY IQWIG
    Siebert, U.
    Muehlberger, N.
    Conrads-Frank, A.
    Sroczynski, G.
    Schwarzer, R.
    VALUE IN HEALTH, 2009, 12 (07) : A225 - A225
  • [38] Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial
    Wagner, Monika
    Lindgren, Peter
    Merikle, Elizabeth
    Goetghebeur, Mireille
    Joensson, Bengt
    CANADIAN JOURNAL OF CARDIOLOGY, 2009, 25 (11) : E362 - E369